Shares of Savient Pharmaceuticals Inc. tumbled 73.5 percent Monday after the company presented data on its pegloticase (Puricase) for treatment-resistant gout. Even though the drug has met its endpoint in two Phase III studies, analysts were skeptical about a key safety issue, its prospects for approval, and the size of its market if it is approved. (BioWorld Today) Read More
